Nan Fung Group Holdings Ltd

Q2 2025 13F Combination Report, Stock Holdings

Signature - Title
Tang Chun Wai Nelson - Director
Location
Kai Tak, Hong Kong
Holdings as of
30 Jun 2025
Value $
$63,431,048
Num holdings
20
Filing time
13 Aug 2025, 16:09:49 UTC
Form type
13F-HR
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). Top holdings included HRMY, ILMN, OCS, INCY, and ONC.
Previous filing
Q1 2025 - 14 May 2025
Next filing
Q3 2025 - 13 Nov 2025
SEC
View on sec.gov
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2025 Q2 compared to 2025 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
Tang Chun Wai Nelson Director Kai Tak, Hong Kong 13 Aug 2025

List of Other Managers Reporting for Nan Fung Group Holdings Ltd:

Name Holdings Value Location File Number
Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631
Pivotal bioVenture Partners Investment Advisor LLC $258,658,319 San Francisco, CA 028-20630

Other Included Managers (2):

Num Name Location File Number
1 Pivotal bioVenture Partners Investment Advisor LLC San Francisco, CA 028-20630
2 Pivotal bioVenture Partners Fund I U.G.P. Ltd San Francisco, CA 028-20631